Vertex drops second telaprevir combo arm from Phase II study
This article was originally published in Scrip
Executive Summary
For the second time in recent months, Vertex Pharmaceuticals has halted testing of a combination of twice-daily dosages of its experimental hepatitis C virus drugs telaprevir 1,125 mg and VX-222 400 mg after a predefined stopping rule showed viral breakthrough in a Phase II trial.